ClinicalTrials.gg
RecruitingNCT07362667Updated Jan 23, 2026

A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA

An observational study in ABPA, Allergic Bronchopulmonary Aspergillosis and Allergic Bronchopulmonary Aspergillosis (ABPA), sponsored by Qianfoshan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Qianfoshan Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
44
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Aspergillosis, Allergic Bronchopulmonary · China.

Started
2026
with 2 others
Observational
9 of 11
9 open now
Primary completion
2028-12
later than 6 of 10 live
Registered
5th of 11
by date
Lead sponsor
9 of 11
Qianfoshan Hospital

Among the 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China, this one is one of 3 that started in 2026, is one of 9 observational ones, reaches primary completion later than 6 of the 10 other live ones, and was the 5th registered.

Aspergillosis, Allergic Bronchopulmonary

42 studies on the registry are indexed under Aspergillosis, Allergic Bronchopulmonary; 13 are open to participants now.

Browse Aspergillosis, Allergic Bronchopulmonary studies →

Open to participants now

11 of the 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Aspergillosis, Allergic Bronchopulmonary studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Aspergillosis, Allergic Bronchopulmonary with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis

03

Conditions studied

  • ABPA
  • Allergic Bronchopulmonary Aspergillosis
  • Allergic Bronchopulmonary Aspergillosis (ABPA)
  • Airway Clearance
  • Mucus Plug
  • Amphotericin B
  • Bronchoscope

Keywords

  • Allergic Bronchopulmonary Aspergillosis
  • ABPA
  • Amphotericin B
  • bronchoscope
  • Airway Clearance
  • mucus plug
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients diagnosed with allergic bronchopulmonary aspergillosis included patients with newly diagnosed allergic bronchopulmonary aspergillosis and patients with acute exacerbation of allergic bronchopulmonary aspergillosis after drug withdrawal.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).
  2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a > 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.
  3. Age ≥ 18 years old.

Exclusion criteria

Exclusion Criteria:

  1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);
  2. Patients with absolute or relative to electronic bronchoscopy;
  3. Known history of allergy to amphotericin B or any of its ;
  4. Patients with bronchiectasis caused by infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;
  5. Combined with other diseases requiring long-term systemic use of or (such as diseases);
  6. Patients with previous or current smoking history;
  7. Pregnant or lactating women;
  8. Currently participating in other interventional clinical research;
  9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \<1 year, or severe mental illness that prevented cooperation).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
44 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Observation group

    The observation group was treated with standard drug therapy (oral glucocorticoids combined or not combined with oral antifungal drugs), combined with bronchoscopic airway clearance and amphotericin B spraying treatment

    Procedure: The patients were treated with bronchoscopic airway clearance and amphotericin B spraying

  • Control group

    Control group: The control group was treated with standard drug therapy (oral glucocorticoids with or without oral antifungal drugs). The previous treatment for bronchial asthma was maintained, including inhaled corticosteroids + long-acting β-receptor agonists, leukotriene receptor antagonists, etc.

Interventions

  • ProcedureThe patients were treated with bronchoscopic airway clearance and amphotericin B spraying

    In addition to standard medical therapy (oral glucocorticoids with or without oral antifungal agents), bronchoscopic airway clearance and bronchoscopic spraying of amphotericin B (depending on the effectiveness of bronchoscopic mucus plug removal, At least one time of bronchoscopic airway clearance and amphotericin B spraying). The previous treatment for bronchial asthma was maintained, including inhaled corticosteroids + long-acting β-receptor agonists, leukotriene receptor antagonists, etc.

06

What researchers measure

Primary outcomes

  1. Radiographic response rate after 4 months of treatment

    Radiographic remission: defined as the removal of mucus plugs in the airway on radiographic examination

    Time frame: 4 months

  2. Immunological remission rate after 4 months of treatment

    Immunological remission: defined as at least a 50% decrease in total serum IgE from baseline

    Time frame: 4 months

  3. The remission rate of clinical symptoms after 4 months of treatment

    Clinical symptom relief: The semi-quantitative rating of clinical symptoms was evaluated using Likert scores with at least 50% improvement in symptoms

    Time frame: 4 months

Secondary outcomes

  1. Number of acute exacerbations within 1 year of drug withdrawal after 4 months of treatment

    Time frame: 1 year

  2. Number of acute exacerbations within 2 years after 4 months of treatment

    Time frame: 2 years

  3. Treatment response rate at 8 weeks

    Time frame: 8 weeks

  4. Number of hospitalizations due to acute exacerbations of allergic bronchopulmonary aspergillosis

    Time frame: 2 years

  5. Time from discontinuation to first exacerbation

    Time frame: 2 years

  6. After drug withdrawal, the number of patients who achieved treatment remission

    The remission phase was defined as sustained (\>6 months) clinical-radiologic improvement in the absence of (or discontinuation of) glucocorticoid therapy and the absence of an increase in total serum IgE of 50% or more from the last recorded value during the stable phase

    Time frame: 2 years

  7. Quality of life score (AQLQ or mini-AQLQ)

    Time frame: 2 years

  8. Serum total IgE

    Time frame: 2 years

  9. All-cause mortality

    Time frame: 2 years

  10. psychological Scale (Hospital Anxiety and Depression Scale, HADS)

    Time frame: 2 years

  11. Aspergillus fumigatus sIgE

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
    Jinan, Shandong 250014, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2025
First posted
Jan 23, 2026
StartActual
Jan 10, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362667
Responsible party
Qian Qi (Prof., Qianfoshan Hospital) — Principal investigator
First posted
Jan 23, 2026
Start date
Jan 10, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 23, 2026

Study contacts

Qian Qi, Dr.
Contact
qiqianqlh@163.com
+86 13706380314

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion